

1 **Molecular malaria surveillance using a novel protocol for extraction** 2 **and analysis of nucleic acids retained on used rapid diagnostic tests**

3

4 Etienne A. Guirou ^{a,b,¶}, Tobias Schindler ^{a,b,¶,*}, Salome Hosch ^{a,b}, Olivier Tresor Donfack ^c, Charlene
5 Aya Yoboue ^{a,b}, Silvan Krähenbühl ^{a,b}, Anna Deal ^{a,b}, Glenda Cosi ^{a,b}, Linda Gondwe ^{a,b,d}, Grace
6 Mwangoka ^d, Heavenlight Masuki ^e, Nahya Salim ^e, Maxmillian Mpina ^{a,b,d}, Jongo Said ^d, Salim Ab-
7 dulla ^d, Stephen L. Hoffman ^f, Bonifacio Manguire Nlavo ^g, Carl Maas ^g, Carlos Cortes Falla ^c, Won-
8 der P. Phiri ^c, Guillermo A. Garcia ^c, Marcel Tanner ^{a,b} and Claudia Daubenberger ^{a,b,*}

9

10 ^aDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Insti-
11 tute, Basel, Switzerland

12 ^bUniversity of Basel, Basel, Switzerland

13 ^cMedical Care Development International, Malabo, Equatorial Guinea

14 ^dIfakara Health Institute, Bagamoyo Branch, United Republic of Tanzania

15 ^eDepartment of Paediatrics and Child Health, Muhimbili University of Health and Allied Sciences,
16 Dar Es Salaam, Tanzania

17 ^fSanaria Inc., Rockville, Maryland, USA

18 ^gMarathon EG Production Ltd, Malabo, Equatorial Guinea

19

20 ¶These authors contributed equally to this work.

21 * Corresponding authors: tobias.schindler@swisstph.ch, claudia.daubenberger@swisstph.ch

22 **Abstract**

23 The use of malaria rapid diagnostic tests (RDTs) as a source for nucleic acids that can be analyzed
24 via nucleic acid amplification techniques has several advantages, including minimal amounts of
25 blood, sample collection, simplified storage and shipping conditions at room temperature. We have
26 systematically developed and extensively evaluated a procedure to extract total nucleic acids from
27 used malaria RDTs. The co-extraction of DNA and RNA molecules from small volumes of dried
28 blood retained on the RDTs allows detection and quantification of *P. falciparum* parasites from
29 asymptomatic patients with parasite densities as low as 1 Pf/ μ L blood using reverse transcription
30 quantitative PCR. Based on the extraction protocol we have developed the ENAR (Extraction of
31 Nucleic Acids from RDTs) approach; a complete workflow for large-scale molecular malaria sur-
32 veillance. Using RDTs collected during a malaria indicator survey we demonstrated that ENAR pro-
33 vides a powerful tool to analyze nucleic acids from thousands of RDTs in a standardized and high-
34 throughput manner. We found several, known and new, non-synonymous single nucleotide poly-
35 morphisms in the propeller region of the kelch 13 gene among isolates circulating on Bioko Island,
36 Equatorial Guinea.

37

38 **Keywords**

39 Nucleic Acid Extraction, Molecular Malaria Surveillance, Rapid Diagnostic Test (RDT), Reverse
40 Transcription Quantitative Polymerase Chain Reaction (RT-qPCR), Artemisinin resistance, kelch 13

41 Introduction

42

43 Malaria remains a global public health issue with an estimated 228 million cases resulting in an esti-
44 mated 405,000 deaths in 2018¹. *P. falciparum* (*Pf*) is the most pathogenic malaria species account-
45 ing for the vast majority of malaria cases and deaths. Malaria surveillance, the continuous and sys-
46 tematic collection, analysis and interpretation of epidemiological data, is the core monitoring and
47 evaluation tool for malaria control programs, and provides the framework for effective allocation of
48 resources². A critical surveillance measure, which closely reflects malaria transmission intensity, is
49 the parasite rate; the proportion of the population found to carry parasites in their peripheral
50 blood^{3,4}. Malaria rapid diagnostic tests (RDTs) are the most widely used technique to measure para-
51 site rates in endemic countries. In sub-Saharan Africa, RDTs have almost completely replaced light
52 microscopy for malaria diagnosis, with an estimated 75% of malaria tests conducted using RDTs in
53 2017¹. RDTs are relatively low cost, provide fast result turnaround time, are widely available and
54 easy to use. However, there are also disadvantages including low sensitivity, resulting in poor per-
55 formance among asymptomatic individuals⁵ and the widespread emergence of *pfhrp2* deletions in
56 certain regions⁶ whereby RDTs fail to detect malaria infection.

57 Nucleic amplification techniques (NATs), such as polymerase chain reaction (PCR), not only show
58 higher sensitivities than RDTs^{5,7} but also allow further characterization of *Pf* isolates using molecu-
59 lar markers. Surveillance of drug-resistant *Pf* strains, based on analysis of resistance-associated mo-
60 lecular markers, is a widely used and valuable epidemiological tool⁸. In sub-Saharan Africa, mal-
61 aria treatment relies heavily on artemisinin-based combination therapy (ACT). The implementation
62 of surveillance programs for early detection of emerging artemisinin-resistant *Pf* strains will be the
63 key to prevent the spread across the continent⁹. Artemisinin-resistant *Pf* strains were first reported in
64 Cambodia^{10,11} and remain a public health concern in South East Asia but have not yet been found to
65 be widespread in Africa, South America or Oceania¹². Non-synonymous mutations in the propeller

66 region of the *Pf* kelch 13 gene (pfk13) were discovered as molecular markers for artemisinin resist-
67 ance¹³.

68 Residual blood from RDTs are an ideal source for nucleic acids (NAs) to be used for NAT-based re-
69 sistance markers screening and present several advantages, including simplicity and cost-effective-
70 ness of sample collection, as well as simplified storage and shipping conditions at room temperature
71 (RT). Over the past decade, several reports have been published describing the use of DNA ex-
72 tracted from used RDTs for molecular analysis of malaria parasites (studies summarized in Supple-
73 mentary Table S1)^{14–24}. However, most studies that tried to address the question of using RDTs as
74 source of DNA were conducted with small sample sizes and focused on demonstrating the feasibil-
75 ity of extracting DNA rather than fitting this approach for molecular surveillance of malaria at
76 larger scale. We identified three key areas that are critical to develop a surveillance tool based on
77 molecular analysis of used RDTs: i) accessing a representative collection of RDTs and creating an
78 effective selection and sorting strategies for RDTs of interest. ii) high-throughput extraction and
79 analysis of NAs from RDTs with minimal hands-on time and focus on reproducibility and quality
80 control throughout the entire extraction process. iii) increasing recovery of *Pf* NAs during the ex-
81 traction process in order to include asymptomatic individuals with low parasite density infections.

82 This manuscript outlines an overall strategy and the protocols for collecting, sorting and processing
83 RDTs to extract the retained NA at large-scale in order to screen for single nucleotide polymorph-
84 isms (SNPs) in an artemisinin-resistance molecular marker in a dataset of thousands of healthy,
85 malaria asymptomatic individuals. We systematically developed and extensively evaluated a proce-
86 dure to extract NA from RDT. The “Extraction of Nucleic Acids from RDTs” (referred to as ENAR)
87 approach is supported by custom-made software solutions that allow the analysis of thousands of
88 RDTs in a standardized, reproducible and high-throughput manner.

89 We developed the ENAR approach in Tanzania and implemented the ENAR approach within Bioko
90 Island Malaria Elimination Project’s (BIMEP) 2018 malaria indicator survey (MIS) conducted on

91 Bioko Island, Equatorial Guinea. BIMEP is an island-wide intervention resulting in a substantial re-
92 duction in malaria, achieving a reduction in parasitemia of around 75% over the past 15 years²⁵. De-
93 spite these achievements, malaria transmission remains stable on Bioko for an number of reasons,
94 and recently a *Pf* isolate of African origin with artemisinin-resistance, including a novel non-syn-
95 onymous mutation in *pfk13*, was identified in a 43-year-old man returning to China from Equatorial
96 Guinea²⁶. This reality underlies the importance of incorporating molecular techniques as monitoring
97 and evaluation tools in malaria control programming.

98

99 **Results**

100

101 **Blood stored on RDTs is a source of *Pf* DNA**

102 First, we conducted a literature search of reports describing the use of NA extracted from RDTs as
103 input templates for NAT-based detection of malaria parasites (Supplementary Table S1). A total of
104 11 studies were published between 2006 and 2019. All studies were limited to the extraction of
105 DNA and used a variety of different extraction methods. Most extraction protocols were based ei-
106 ther on the Chelex method (n=7) or silica column-based DNA extraction kits (n=6). One study ex-
107 tracted DNA from the entire RDT strip, all other studies used only predefined fragments of the RDT
108 strip. These previous studies demonstrated that *Pf* DNA can be recovered from RDTs and amplified
109 by NATs. Several studies genotyped drug resistance associated markers using sanger or next genera-
110 tion sequencing.

111 As the majority of these studies extracted DNA from RDTs of febrile clinical malaria cases, indicat-
112 ing high parasite densities, we first conducted a study to test feasibility of detecting *Pf* DNA from
113 RDTs of asymptomatic individuals. We employed RDTs collected in a malaria survey conducted
114 among asymptomatic children from three primary schools in the Mkuranga district of Coastal Tan-
115 zania. DNA was extracted from 190 RDTs and *Pf* DNA was recovered from 90.8% (59/65) of
116 PfHRP2-positive RDTs, from 100% (5/5) of PfHRP2/pLDH-positive RDTs and from 11.7%
117 (14/120) negative RDTs (Fig 1A).

118 Encouraged by the outcome of the school-based survey, we aimed to improve the extraction method
119 from RDTs. As a proxy for the amount of extracted NAs, the Cq value of the human *rnasep* gene
120 (HsRNaseP target), which is the internal control of the previously published PlasQ assay, was used
121 to assess the overall performance of four different extraction procedures (Fig 1B). Side-by-side
122 comparison of the four extraction procedures, named Protocol A through D, confirmed the superior
123 performance of protocols B and D. Considering the costs and the fact that protocol D co-extracts

124 RNA, we developed protocol D, which we renamed ENAR (Extraction of Nucleic Acids from
125 RDTs). In order to identify the part of the RDT strip where most *Pf* NAs accumulate, we analyzed
126 the sample pad (proximal part), the detection area (middle part), and the absorption pad (distal part)
127 using ENAR. In RDTs probed with fresh blood, *Pf* NAs are found in all three parts, with more than
128 87% of the total extracted DNA concentrated in the middle part. RDTs spiked with frozen blood that
129 is associated with red blood cell lysis resulted in an equal distribution of NA along the entire RDT
130 strip (Supplementary Figure S1).

131

132 **Detection and quantification of *Pf* parasites based on ENAR protocol**

133 We evaluated the ENAR protocol with cultured *Pf* strains including the strains PfDD2, PfHB3 and
134 PfNF54 by preparing ten-fold serial dilutions in whole blood with parasite densities corresponding
135 to 0.1 – 1000 Pf/ μ L. RDTs were spiked with 5 μ L of diluted cultures, the NAs extracted by ENAR,
136 and analyzed by qPCR and RT-qPCR (Fig 1C). Only the RT-qPCR assay resulted in detection of all
137 three strains with the 1 Pf/ μ L parasite density. Furthermore, the Psp18S-based RT-qPCR assay
138 even detected two (PfDD2 and PfNF54) out of the three *Pf* strains at a concentration of 0.1 Pf/ μ L.
139 This result demonstrates that the ENAR clearly co-extracts DNA and RNA. The *Pf* 18S ribosomal
140 RNA, detected by the Psp18S RT-qPCR assay, is constantly and highly expressed during the life
141 cycle of the parasite^{27,28}, while the acidic terminal sequence of the var genes (PfEMP1), detected by
142 the PfvarATS assay, is associated with lower RNA levels²⁹. The ability of the ENAR protocol to co-
143 extract DNA and RNA was also demonstrated with the following experiment: Five μ L of an *in*
144 *vitro*-generated stage V gametocyte culture was applied onto the RDTs and stored at RT for three
145 weeks before NAs were extracted by ENAR. The gametocyte-specific transcript PF3D7_0630000
146 was reverse transcribed and amplified using a published assay which does not require DNase treat-
147 ment for specific detection of gametocytes³⁰. Extracted NAs from 5 μ L undiluted and 1:100 diluted

148 stage V gametocytes specifically amplified the gametocyte marker, while the control without a re-
149 verse transcription step did not result in amplification (Supplementary Figure S2).

150 The PfIS, an international standard with known parasite density, was used to explore the feasibility
151 of quantifying *Pf* parasites extracted by ENAR. In total, 51 individual RDTs containing 5 μ L PfIS
152 with different parasite densities, ranging from 0.1 to 10,000 Pf/ μ L of the PfIS, were prepared. A
153 high reproducibility and reverse correlation between parasite densities and Cq values were observed
154 for both targets, the *Pf* specific PfvarATS and the pan-*Plasmodium* target Psp18S (Fig 1D). Based
155 on the slope, RT-qPCR efficiencies of 75.4% and 124.3% were calculated for PfvarATS and Psp-
156 p18S, respectively. RDTs negative for PlasQ assay amplification (Cq > 45, colored in red) carried
157 mostly dilutions representing parasite densities ≤ 1 parasite/ μ L. Two exceptions were observed
158 where the Psp18S assay failed to amplify two RDTs probed with higher parasitemia levels (5 and
159 10 Pf/ μ L, respectively). RDTs probed with 1 parasite/ μ L were detected in 4 (PfvarATS) and 7 (Psp-
160 p18S) out of 10 RDTs tested.

161 In summary, based on experiments conducted with standardized *Pf* reference samples we conclude
162 that ENAR is able to recover both DNA and RNA, which results in an increased sensitivity of the
163 RT-qPCR compared to the qPCR-based detection methods. The lower limit of detection (LOD) for
164 RT-qPCR-based amplification of NAs from RDTs is around 1 Pf/ μ L, although 10x lower para-
165 sitemia levels can be detected as demonstrated with freshly cultured *Pf* parasites. RDTs are a reli-
166 able source of NAs and extraction by ENAR followed by analysis using RT-qPCR assays allows
167 quantification of *Pf* parasites.

168

169 **Evaluation of ENAR protocol using Controlled Human Malaria Infection studies as a** 170 **platform**

171 Blood collected from volunteers undergoing Controlled Human Malaria Infection (CHMI) studies
172 represent well-characterized samples as the parasite strain, the timing and dosing of infection is

173 known. Therefore, blood samples collected from volunteers undergoing CHMI are well suited for
174 developing and validating novel malaria diagnostic tools³¹.

175 The ENAR protocol was evaluated with venous blood samples collected during CHMIs assessing
176 the efficacy of Sanaria's PfSPZ Vaccine in clinical trials in Bagamoyo, Tanzania in malaria pre-ex-
177 posed volunteers. RDTs were spiked with blood and stored as part of two CHMIs, the first of which
178 was conducted in 2016 (CHMI-1) and the second in 2018 (CHMI-2). As part of the standard diag-
179 nostic procedures during the CHMIs, whole blood was collected in EDTA tubes and DNA extracted
180 from a total of 180 μL whole blood. A DNA-based qPCR assay was run and parasitemia quantified
181 (defined as WB-qPCR). Parasite densities as low as 0.05 Pf/ μL are detected with the WB-qPCR
182 protocol. During both CHMIs, fresh blood from asymptomatic subjects collected 9 to 18 days post-
183 CHMI was tested with RDTs (Table 1). CHMI-1 and CHMI-2 used two different types of RDTs,
184 which required 20 μL and 5 μL of whole blood, respectively. RDTs collected during CHMI-1 were
185 stored for an average of 605 days (categorized as > 18 months), while RDTs collected during
186 CHMI-2 were stored for an average of 18 days (< 1 month) before processing following the ENAR
187 protocol. For the entire storage period, RDTs were kept at RT in a closed box and protected from
188 light. NAs were extracted from the RDTs using the ENAR protocol and parasites were detected and
189 quantified by RT-qPCR using the PlasQ assay.

190

191 **Table 1. Overview of blood samples collected during two CHMIs and stored on RDTs.**

192

193 **Impact of long-term storage on detection rate of parasite NA extracted by ENAR**

194 First, we analyzed the impact of RDT storage time on parasite detection rates. Long-term storage (>
195 18 months) negatively affects the *Pf* detection rate in samples with a parasite density between 1 and
196 10 Pf/ μL but has no negative impact on samples with initial parasite density greater than 10 Pf/ μL
197 (Fig 2A). Long-term storage negatively affects the detection rate based on the Psp18S target (33%

198 vs 100%, Fisher's exact test $p = 0.06$) more than the PfvarATS target (66% vs 100%, Fisher's exact
199 test $p = 0.46$). Interestingly, the parasite densities estimated from RDTs with shorter storage time (<
200 1 month) are closer to the reference parasite densities assessed by WB-qPCR using 180 μ L freshly
201 prepared blood than the estimates from RDTs with longer storage time (> 18 months) (Fig 2B). This
202 is an additional indicator that NAs conserved on RDTs might undergo degradation over time.

203 204 **Clinical sensitivity and parasite quantification based on ENAR approach**

205 If the data of both CHMIs are combined, the overall detection rate was 54% for the ENAR-based
206 RT-qPCR when compared to WB-qPCR, which was significantly higher than detection by mi-
207 croscopy (9%) or PfHRP2 antigen capture by RDT (12%) using the same samples.

208 In order to understand the contribution of RNA on the detection rates in this clinical sample set, we
209 compared RT-qPCR with qPCR. Detection rates of RT-qPCR in relation to parasite density reveals
210 an improved diagnostic performance over the whole range of *Pf* densities compared to qPCR (Fig
211 2C). RT-qPCR is significantly more sensitive than qPCR for the Pspp18S assay (27% vs 47%, Mc-
212 Nemar test $p=0.0026$), but not for the PfvarATS assay (47% vs 47%, McNemar test $p=1.0$). Interest-
213 ingly, among the long-term stored RDTs collected in 2016, the detection rate of the Pspp18S assay
214 was also significantly higher for RT-qPCR compared to qPCR (52% vs 22%, McNemar test p
215 $=0.01$). Even after long-term storage a significant proportion of (fragmented) RNA can be still ex-
216 tracted and used for RT-qPCR amplification.

217 Parasite densities determined by WB-qPCR versus densities obtained with the ENAR-based RT-
218 qPCR method showed significant positive correlation supporting the quantitative character of our
219 approach (Fig 2D). The correlation was stronger with the PfvarATS assay ($r^2 = 0.72$) than with the
220 Pspp18S assay ($r^2 = 0.39$).

221

222 **Implementation of ENAR protocol within malaria indicator survey**

223 We implemented the ENAR approach within a malaria indicator survey in which we aimed to
224 screen for SNPs in the pfk13 propeller region to study the prevalence and type of mutations poten-
225 tially associated with artemisinin resistance. We tested ENAR using samples and data derived from
226 the 2018 BIMEP MIS which included more than 13,000 individuals (Fig 3A). Instead of disposing
227 the RDTs after use, the tests were labeled with a barcode to connect each RDT with other survey
228 data collected in questionnaires (Fig 3B). For each of these barcode-labeled RDTs, an extra in-
229 formed consent for molecular analysis was obtained from the participants or their legal guardians.
230 For the sorting and selection of distinct RDTs for analysis, we developed the *RDTselect* app ([https://](https://github.com/Sparclex/barcode-value-finder)
231 github.com/Sparclex/barcode-value-finder), a browser-based mobile phone application which iden-
232 tifies barcode-labeled RDTs based on an input list containing all barcodes of a certain selection (Fig
233 3C).

234 To enable tracking of an individual RDT throughout the ENAR extraction process the *RDTallocator*
235 app (<https://github.com/Sparclex/position-allocator>) was programmed. The barcodes are scanned
236 with a mobile phone camera and the *RDTallocator* app allocates the associated RDT strip to the
237 next available position in a 96-well plate (Fig 3C). After opening the RDT shell the entire uncut
238 RDT strip is removed with sterile, single-use forceps (Fig 3D), incubated with lysis buffer in a 12-
239 well long-format plate (Fig 3E), and NAs are extracted in a high-throughput 96-well format of the
240 ENAR protocol (Fig 3F). All extracted samples undergo initial screening for presence of *Plas-*
241 *modium* spp. parasites and quality control using the PlasQ RT-qPCR assay (Fig 3G). All RT-qPCR
242 data generated were managed and analyzed by a custom-designed laboratory management and in-
243 formation system. ELIMU-MDx is designed for automated quality control, management and analy-
244 sis of qPCR data³² (Fig 3H). Samples positive for *Pf* were subjected to amplification and sequencing
245 of pfk13 for identification of SNPs associated with drug resistance (Fig 3I).

246 A total of 2690 out of 13,270 (20.3%) RDTs were extracted by ENAR and analyzed for *Plasmod-*
247 *ium* spp. parasites by RT-qPCR. The demographic information of the entire MIS population and the
248 selected volunteers for the molecular analysis are given in Table 2. Only volunteers with body tem-
249 perature < 37.5 °C were included. Volunteers with a positive RDT and pregnant women are inten-
250 tionally over-represented in our sample set.

251

252 **Table 2. Demographic information of MIS participants.**

253

254 **Malaria infections among asymptomatic MIS participants are characterized by *Pf* infections**
255 **with mainly low parasite densities**

256 Applying the approach described in Figure 3, 30.8% (828/2690) of the analyzed RDTs tested posi-
257 tive for *Plasmodium* spp. NAs (Table 3). A qPCR-based species identification revealed that 92.9%
258 were *Pf*, 4.0% *P. malariae* and 1.0% *P. ovale* spp. No *P. vivax* or *P. knowlesi* NAs were found. In
259 this asymptomatic population, *Pf* infections had on average parasite density of 29.2 Pf/μL, with
260 densities being the highest among children below the age of five years (Fig 4a). The rather low par-
261 asitemia levels of asymptomatic individuals in combination with the small amount of blood avail-
262 able have implications for pfk13 genotyping. Samples with parasitemia levels below 50 Pf/μL are
263 rarely amplified successfully for pfk13 sequencing (Fig 4b). In order to increase the efficiency of
264 pfk13 genotyping process from RDTs, pre-selection based on RDT result is advised. For example,
265 84.5% of RDTs positive for both, PfHRP2 and pLDH carried parasite densities high enough to re-
266 sult in successful amplification of the pfk13 propeller region.

267

268 **Table 3. ENAR-based identification of malaria parasites using PlasQ RT-qPCR assay.**

269

270 **Low prevalence of SNPs in the pfk13 propeller region among *Pf* parasite isolates on Bioko**

271 Sequence analysis of the pfk13 propeller region revealed a low prevalence of SNPs (Table 4).
272 97.6% (283/290) of Bioko's *Pf* isolates carried the wildtype allele. Two isolates had the A578S and
273 one the V589I non-synonymous SNP, which have been described in sub-Saharan Africa before^{12,33}
274 and are not associated with artemisinin resistance³⁴. The P553L SNP was first described in Cambo-
275 dia¹³. This SNP has previously been found at low prevalence in East Africa, in Kenya and Malawi³⁵
276 as well as recently found in an isolate from a Chinese national returned from Angola³⁶. To our
277 knowledge, the V517I SNP has never been described before. Compared to the other three known
278 SNPs, the V517I SNP had the lowest PROVEAN³⁷ score, indicating no or neutral effects on the bio-
279 logical function of the kelch 13 protein. Two synonymous SNPs, namely, V510V and C469C, were
280 also found.

281

282 **Table 4. *Pfk13* propeller polymorphisms observed in MIS population on Bioko Island.**

283 Discussion

284

285 This report presents the development of an approach for large-scale, high-throughput and cost effi-
286 cient molecular surveillance of malaria parasites based on extraction of NAs from RDTs. During the
287 development of ENAR, special attention was given to the evaluation of its reproducibility and the
288 impact of long-term storage on the detectability of the NAs. Using samples from CHMI studies as a
289 standardized platform allowed us to conclude that NAs can be reliably recovered and amplified
290 from RDTs, even after long-term storage at RT. The small amount of blood in combination with low
291 parasite density is a challenge when it comes to detecting *Pf* in asymptomatic patients. Therefore,
292 we aimed to maximize the amount of NA recovered from RDTs by expanding the pool of possible
293 target molecules to RNA by using RT-qPCR. Even after a storage period of over 18 months at RT,
294 the detection rate of the RT-qPCR assay was still significantly higher compared to qPCR only, indi-
295 cating long-term preservation of DNA and RNA.

296 We aimed to transform the ENAR approach into an flexible tool for larger scale surveillance studies
297 by increasing extraction and analysis throughput. The ENAR approach was successfully integrated
298 into the 2018 BIMEP MIS on Bioko Island. More than 13,000 individuals gave extra consent for
299 storage and molecular analysis of their RDT. This high acceptance rate was also described by oth-
300 ers²¹ and can be attributed to the convenience of blood collection by finger prick and the small
301 blood volume, usually 5 to 10 μ L, needed for RDTs. With a total of 2750 RDTs, we analyzed blood
302 from more than 20% of the MIS participants. This was made possible by the development of cus-
303 tom-made software solutions for sorting and identification of RDTs and by a significant reduction in
304 processing time by using the entire RDT strip instead of cutting it into pieces.

305 Robust (quantitative) data, as generated by ENAR, in combination with a large-scale MIS adds sub-
306 stantial value to our understanding of malaria endemicity on Bioko Island without conducting addi-
307 tional expensive and time consuming epidemiological studies. In addition this process allows for re-

308 searches to detect various species of malaria parasites. For instance, we found *P. malariae* and *P.*
309 *ovale* spp., but did not find *P. vivax*, as in previous studies when surveys carried out in 1996 and
310 1998 found two³⁸ and one³⁹ case of *P. vivax* infection on Bioko Island.

311 In addition, we screened for SNPs in the propeller region of the *pfk13* gene among asymptomatic
312 individuals to obtain data of possible artemisinin-resistant *Pf* strains circulating on the island. We
313 found that 1.7% (5/290) of the analyzed *Pf* isolates had non-synonymous SNPs in the *pfk13* propel-
314 ler region, which is comparable to the prevalence found in other African countries³³. Among the
315 five isolates with non-synonymous SNPs, two isolates had the A578S, one the V589I, one the
316 P553L and one the V517I SNP. The A578S and V589I allele had been reported in the region al-
317 ready^{40,41}, and we found one new previously unreported non-synonymous SNP, V517I. Interestingly,
318 the P553L SNP is the only mutation we found which was previously associated with delayed para-
319 site clearance¹². Although the prevalence of *pfk13* SNPs seems to be low in the moment, the spread
320 of *Pf* parasites with *pfk13* SNPs needs to be closely monitored. A molecular surveillance approach
321 as presented may offer a unique opportunity to support policy makers regarding choice and change
322 of drugs for malaria treatment⁴².

323 Based on the presented results, we propose that ENAR provides a powerful tool for molecular
324 malaria surveillance and could be reliably used for retrospective quantitative and in-depth molecular
325 studies of malaria.

326 **Material and methods**

327

328 ***Pf* reference samples**

329 *Pf* reference samples were used to test the performance of the ENAR procedure. Experiments with
330 *Pf* reference samples were conducted using Carestart™ HRP2/pLDH Combo RDTs (Access Bio,
331 Inc., Somerset, NJ, USA). Serial dilutions of the WHO International Standard for *Pf* DNA Nucleic
332 Acid Amplification Techniques (NIBSC code: 04/176, herein referred to as PfIS)⁴³ were used to
333 quantify *Pf* parasitemia by (RT)-qPCR. Whole blood was spiked with different parasite densities,
334 ranging from 10,000 to 0.1 Pf/μL and 5 μL of this suspension applied onto RDT.

335 Additionally, ten-fold serial dilutions, ranging from 10,000 to 0.1 Pf/μL, of freshly cultured *Pf*
336 strains PfNF54, PfDD2 and PfHB3 were prepared and 5 μL were applied onto RDTs. 5 μL of stage
337 V gametocytes were obtained from *in vitro* parasite culture as described previously⁴⁴. RDTs probed
338 with these stage V gametocytes were extracted using the ENAR protocol after a three-week storage
339 period at RT.

340

341 **School-based survey in Mkuranga district**

342 Carestart™ HRP2/pLDH Combo RDTs were used to determine the parasite rate among asymptomatic
343 children from three primary schools in the Mkuranga district of Coastal Tanzania. Extraction
344 protocol A, which is based on the Quick-DNA™ Miniprep Kit (Zymo Research Corporation, Irvine
345 CA, USA), was used to extract DNA from a total of 190 RDTs collected during this school-based
346 survey. *Pf* was detected by amplifying the acidic terminal sequence of the var genes (PfvarATS)⁴⁵.

347

348 **Sample collection, analysis and storage during CHMI studies**

349 RDTs were collected during two CHMI studies conducted to evaluate Sanaria's PfSPZ Vaccine in
350 Bagamoyo, Tanzania (Clinical Trials.gov registration numbers NCT02613520 and NCT03420053,

351 respectively). The first CHMI was conducted in 2016 (referred to CHMI-1) and the second CHMI
352 was conducted in 2018 (referred to CHMI-2). Fresh venous whole blood collected in EDTA tubes
353 was analyzed by RDTs within 45 min after blood collection. During CHMI-1, 20 μ L was applied to
354 BinaxNOW[®] Malaria RDT (Alere, Cologne, Germany) and during CHMI-2, 5 μ L was applied to
355 Carestart[™] HRP2/pLDH Combo RDT. The RDTs were read according to the manufacturers guide-
356 lines and then stored in a box at RT until extraction of NA.

357 The same samples were used to monitor parasitemia during CHMI by thick blood smear mi-
358 croscopy and qPCR as described elsewhere^{46,47}. All samples were processed and analyzed at the lab-
359 oratory of the Bagamoyo branch of the Ifakara Health Institute in Tanzania.

360

361 **Malaria indicator survey on Bioko Island, Equatorial Guinea**

362 The 2018 BIMEP Malaria Indicator Survey (MIS) was carried out between August and October
363 2018 on a representative sample of 13,505 individuals from 4774 households selected from all com-
364 munities across Bioko Island. All consenting permanent residents and short-term visitors were
365 tested for malaria using the CareStart[™] Malaria HRP2/pLDH Combo RDT. Used RDTs were
366 stored at RT in plastic bags containing desiccants and transported to the Swiss Tropical and Public
367 Health Institute for further molecular analysis.

368

369 **Nucleic acid extraction methods from RDTs**

370 The RDT cassettes were opened, the entire RDT strip removed and cut into four small pieces in or-
371 der to fit into a 1.5 mL micro-centrifuge tube. A set of cleaned forceps and scissors were used with
372 special attention given to prevent cross-contamination between samples. After processing a sample,
373 the scissors and forceps were cleaned in 10% sodium hypochlorite, wiped with ethanol-sprayed tis-
374 sues and dried before processing the next sample. The four nucleic extraction protocols tested,
375 named A through D, were all based on silica columns.

376 *Protocol A – ZR Quick-DNA™ Miniprep Kit:* The protocol is based on the Quick-DNA™ Miniprep
377 Kit (Zymo Research Corporation, Irvine CA, USA). Briefly, 1 mL of Genomic Lysis Buffer was
378 added to the pre-cut RDT strip in a 1.5 mL micro-centrifuge tube and incubated at 95 °C for 20
379 minutes. The mixture was then transferred onto the extraction column and the manufacturers guide
380 was followed for extraction. DNA was eluted in 50 µL of DNA Elution Buffer.

381 *Protocol B – ZR Quick-DNA™ Miniprep Plus Kit:* The protocol is based on the Quick-DNA™
382 Miniprep Plus Kit (Zymo Research Corporation, Irvine CA, USA). We added 600 µL of Solid Tis-
383 sue Buffer (Blue) and 40 µL of Proteinase K to the pre-cut RDT strip in a 1.5mL micro-centrifuge
384 tube and incubated at 55 °C for 60 minutes. The supernatant was transferred to a clean 1.5 mL mi-
385 cro-centrifuge tube and 640 µL of Genomic Lysis Buffer was added and thoroughly mixed. The
386 mixture was transferred onto the extraction column and extracted per manufacturers guidelines.
387 DNA was eluted in 50 µL of DNA Elution Buffer.

388 *Protocol C – NukEx Pure RNA/DNA Kit:* The protocol is based on NukEx Pure RNA/DNA Kit
389 (Gerbion GmbH, Kornwestheim, Germany), which co-extracts DNA and RNA. We created a work-
390 ing solution of 500 µL of Binding Buffer, 4 µL of Poly A and 50 µL of Proteinase K. The working
391 solution was added to the pre-cut RDT strip in a 1.5 mL micro-centrifuge tube following incubation
392 at 60 °C for 10 minutes. The supernatant was transferred onto the NukEx Spin Column and textra-
393 ction was carried out per manufacturer’s guidelines. Total NAs were eluted in 50 µL of Elution Buf-
394 fer.

395 *Protocol D – Zainabadi et al. extraction method for DBS:* The protocol is based on a recently pub-
396 lished extraction protocol for total NAs from dried blood spots⁴⁸. Identical buffer compositions were
397 used, and the protocol was adapted to extraction of NAs from RDT strips. We incubated the pre-cut
398 RDT strip in 900 µL lysis buffer at 60 °C for 2 hours. The supernatant was transferred onto Omega
399 HiBind RNA Mini Columns (Omega Bio-Tek, Norcross, USA) and NAs extracted as described.

400 NAs were eluted in 50 μ L of Elution Buffer (Quick-DNA™ Miniprep Kit, Zymo Research Corpo-
401 ration, Irvine CA, USA).

402

403 **High-throughput extraction protocol of NAs from RDTs (ENAR protocol)**

404 We adapted protocol D to extract NAs from used RDTs in a high-throughput manner. The main
405 modification included a horizontal incubation of the entire uncut RDT strip by using sterile,
406 RNase-/DNase-free 12-channel reservoirs (Axygen, Corning Inc, USA) and switching to a 96-well
407 format for extraction. By removing the cutting step, the hands-on time during the extraction process
408 is significantly reduced, as well the risk of cross-contamination by carryover during the cutting
409 process is minimized. Up to eight 12-channel reservoirs, with a total of 96 samples, were processed
410 in one batch. Lysis was conducted by adding 900 μ L lysis buffer to each RDT strip placed in the 12-
411 channel reservoir followed by incubation at 60 °C for 2 hours with gentle shaking. All supernatants
412 were then transferred to Omega E-Z 96 wells DNA plates (Omega Bio-Tek, Norcross, USA),
413 washed with Wash Buffer 1 and 2 and lastly eluted into a 96 well plate (DNA LoBind Plates, Ep-
414 pendorf) with 50 μ L pre-warmed (60 °C) Elution Buffer (Zymo Research Corporation, Irvine CA,
415 USA). With these adaptations to the protocol, NA from 96 RDTs can be extracted in about three
416 hours, with minimal hands-on time needed. One positive control (RDT spiked with 5 μ L blood con-
417 taining 200 Pf/ μ L) and one negative control (Lysis Buffer only) were included with each extraction
418 plate to control for plate-to-plate consistency and cross-contamination. A standard operating proce-
419 dure (SOP) for ENAR can be found in Supplementary Protocol S1.

420

421 **Detection and quantification of *Plasmodium* spp. parasites**

422 We used the PlasQ assay, a multiplex qPCR assay for *Plasmodium* spp. and *Pf* detection and quan-
423 tification to analyze the NAs extracted from RDTs⁴⁷. The PlasQ assay targets the Pan-*Plasmodium*
424 18S DNA and RNA (Psp18S)^{49,50} and the *Pf*-specific acidic terminal sequence of the var genes (Pf-

425 varATS)⁴⁵. The human *rnasep* gene (HsRNaseP)⁴⁹ served as an internal control to assess the quality
426 of NA extraction and qPCR amplification. To run the PlasQ as a RT-qPCR assay, targeting both
427 DNA and RNA templates, we added 1x Luna WarmStart RT Enzyme Mix (New England Biolabs,
428 Ipswich, USA) and started the RT-qPCR program with a reverse transcription step at 55 °C for 15
429 min. All qPCR and RT-qPCR assays were run on a Bio-Rad CFX96 Real-Time PCR System (Bio-
430 Rad Laboratories, California, USA). Samples were analyzed in duplicate with positive (PfNF54
431 DNA), negative (malaria negative individual) and non-template (molecular biology grade H₂O)
432 controls added to each qPCR run.

433

434 **Multiplex pre-amplification of *Plasmodium* spp. DNA**

435 The *Plasmodium* spp. 18S rDNA and *pfk13* genes of all PlasQ-positive samples were amplified in a
436 multiplex reaction by conventional PCR. We amplified 3 µL of extracted NAs in a total volume of
437 20 µL using 1x HOT FIREPol® MultiPlex Mix (Solis Biodyne, Tartu, Estonia). Using 0.25 µM of
438 the published primers, AGT GGA AGA CAT CAT GTA ACC AG and CCA AGC TGC CAT TCA
439 TTT GT, 986 bp of the *pfk13* propeller region were amplified²⁶. Simultaneously, 1407-1469 bp of
440 the pan-*Plasmodium* 18S rDNA were amplified using 0.5 µM of GRA ACT SSS AAC GGC TCA
441 TT⁵¹ and AGC AGG TTA AGA TCT CGT TCG⁴⁹. The conditions of the multiplex PCR were the
442 following: 95 °C for 12 minutes; 25 cycles of 95 °C for 20 seconds, 57 °C for 40 seconds and 72 °C
443 for 1 minute 45 seconds; and 72 °C for 10 minutes.

444

445 **Detection of gametocytes and *Plasmodium* spp. species identification**

446 *Gametocyte-specific RT-qPCR assay*: A previously published RT-qPCR assay for identification of
447 *Pf* gametocytes based the PF3D7_0630000 transcript was used³⁰. Briefly, 2 µL of extracted NAs
448 were added to 8 µL reaction mix consisting of 0.6 µM of primers, 0.3 µM probe and Luna® Univer-
449 sal Probe One-Step RT-qPCR Kit (New England Biolabs, Ipswich, USA). The qPCR program in-

450 cluded a reverse transcription step for 15 min at 53 °C, followed by polymerase activation for 1 min
451 at 95 °C, and 45 cycles with 15 s at 95 °C and 45 s at 53 °C.

452 *Plasmodium* spp. species identification: Non-*falciparum* *Plasmodium* species identification based
453 on the 18S rDNA gene was performed. 2 µL of the product from the *Plasmodium* spp. multiplex
454 pre-amplification were added to the master mix containing 1x Luna® Universal Probe qPCR Mas-
455 ter Mix, 0.8 µM forward (GTT AAG GGA GTG AAG ACG ATC AGA) and 0.8 µM reverse
456 primers (AAC CCA AAG ACT TTG ATT TCT CAT AA) to amplify a 157- to 165-bp segment of
457 the *Plasmodium* spp. 18S rDNA gene⁵². Species-specific probes were selected to differentiate be-
458 tween the species. *P. malariae* was detected using a Yakima Yellow-labelled MGB probe (CTA TCT
459 AAA AGA AAC ACT CAT)⁵³, *P. ovale* spp. using a novel designed Texas Red-labelled and LNA-
460 modified probe (GGA [LNA-A]AT [LNA-T]TC TTA GAT TGC TTC CT[LNA-T] CAG), *P. vivax* a
461 Cy5-labelled probe (GAA TTT TCT CTT CGG AGT TTA)⁵⁴ and *P. knowlesi* a Cy5-labelled probe
462 (CTC TCC GGA GAT TAG AAC TCT TAG ATT GCT)⁵⁵. The conditions for the qPCR were: 95 °C
463 for 3 minutes and 45 cycles of 95 °C for 15 seconds and 57 °C for 45 seconds.

464

465 **Genotyping of pfk13 propeller region**

466 In a second PCR reaction with a 15 µL total volume, 1.5 µL of the product from the *Plasmodium*
467 spp. multiplex pre-amplification was amplified using 1x HOT FIREPol® MultiPlex Mix (Solis Bio-
468 dyne, Tartu, Estonia) and 0.33 µM forward (TGA AGC CTT GTT GAA AGA AGC A) and reverse
469 (TCG CCA TTT TCT CCT CCT GT) primers. Except for an annealing temperature of 58 °C, the
470 PCR conditions were similar to the first reaction. The 798 bp product of the second PCR was evalu-
471 ated using agarose gel electrophoresis and samples which failed amplification were repeated. Am-
472 plicons were sequenced by Microsynth (Microsynth AG, Balgach, Switzerland).

473

474 **Data analysis and statistics**

475 All (RT)-qPCR assays were run in duplicates and initial data analysis of the (RT)-qPCR data was
476 conducted using CFX Maestro Software (Bio-Rad Laboratories, California, USA). In the case
477 where one replicate interpreted as positive and the other negative, then the assay was repeated and
478 the result was considered positive if two positive replicates were obtained out of the total four repli-
479 cates. All (RT)-qPCR data generated were managed and analyzed by a custom-designed laboratory
480 management and information system named ELIMU-MDx³². The ELIMU-MDx platform supports
481 automated quality control, management and analysis of qPCR data. Oligo design and sequence
482 analysis was performed using Geneious Prime 2019.1.1 (<https://www.geneious.com>). Statistical
483 analysis and visualization of data was conducted using R version 3.5.1 based on packages *dplyr*,
484 *ggpubr*, *ggplot2*, *gridextra*, *reshape2* and *scales*.

485 **References**

486

1. WHO. World malaria report 2018. *World Health Organ.* 210 (2019).
2. WHO | Malaria surveillance, monitoring & evaluation: a reference manual. *WHO* <http://www.who.int/malaria/publications/atoz/9789241565578/en/>.
3. Smith, D. L., Guerra, C. A., Snow, R. W. & Hay, S. I. Standardizing estimates of the *Plasmodium falciparum* parasite rate. *Malar. J.* **6**, 131 (2007).
4. Guerra, C. A. *et al.* Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project. *Malar. J.* **6**, 17 (2007).
5. Hofmann, N. E. *et al.* Assessment of ultra-sensitive malaria diagnosis versus standard molecular diagnostics for malaria elimination: an in-depth molecular community cross-sectional study. *Lancet Infect. Dis.* **18**, 1108–1116 (2018).
6. Gendrot, M., Fawaz, R., Dormoi, J., Madamet, M. & Pradines, B. Genetic diversity and deletion of *Plasmodium falciparum* histidine-rich protein 2 and 3: a threat to diagnosis of *P. falciparum* malaria. *Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.* **25**, 580–585 (2019).
7. Okell, L. C., Ghani, A. C., Lyons, E. & Drakeley, C. J. Submicroscopic infection in *Plasmodium falciparum*-endemic populations: a systematic review and meta-analysis. *J. Infect. Dis.* **200**, 1509–1517 (2009).
8. Diakité, S. A. S. *et al.* A comprehensive analysis of drug resistance molecular markers and *Plasmodium falciparum* genetic diversity in two malaria endemic sites in Mali. *Malar. J.* **18**, 361 (2019).
9. Apinjoh, T. O., Ouattara, A., Titanji, V. P. K., Djimde, A. & Amambua-Ngwa, A. Genetic diversity and drug resistance surveillance of *Plasmodium falciparum* for malaria elimination: is there an ideal tool for resource-limited sub-Saharan Africa? *Malar. J.* **18**, 217 (2019).
10. Dondorp, A. M. *et al.* Artemisinin Resistance in *Plasmodium falciparum* Malaria. *N. Engl. J. Med.* **361**, 455–467 (2009).

11. Noedl, H. *et al.* Evidence of artemisinin-resistant malaria in western Cambodia. *N. Engl. J. Med.* **359**, 2619–2620 (2008).
12. Ménard, D. *et al.* A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. *N. Engl. J. Med.* **374**, 2453–2464 (2016).
13. Ariey, F. *et al.* A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. *Nature* **505**, 50–55 (2014).
14. Veron, V. & Carme, B. Recovery and use of Plasmodium DNA from malaria rapid diagnostic tests. *Am. J. Trop. Med. Hyg.* **74**, 941–3 (2006).
15. Ishengoma, D. S. *et al.* Using rapid diagnostic tests as source of malaria parasite DNA for molecular analyses in the era of declining malaria prevalence. *Malar. J.* **10**, 6 (2011).
16. Cnops, L., Boderie, M., Gillet, P., Van Esbroeck, M. & Jacobs, J. Rapid diagnostic tests as a source of DNA for Plasmodium species-specific real-time PCR. *Malar. J.* **10**, 67 (2011).
17. Morris, U. *et al.* Rapid diagnostic tests for molecular surveillance of Plasmodium falciparum malaria -assessment of DNA extraction methods and field applicability. *Malar. J.* **12**, 106 (2013).
18. Papa Mze, N. *et al.* RDTs as a source of DNA to study Plasmodium falciparum drug resistance in isolates from Senegal and the Comoros Islands. *Malar. J.* **14**, 373 (2015).
19. Nabet, C. *et al.* Analyzing Deoxyribose Nucleic Acid from Malaria Rapid Diagnostic Tests to Study Plasmodium falciparum Genetic Diversity in Mali. *Am. J. Trop. Med. Hyg.* **94**, 1259–1265 (2016).
20. Boyce, R. M. *et al.* Reuse of malaria rapid diagnostic tests for amplicon deep sequencing to estimate Plasmodium falciparum transmission intensity in western Uganda. *Sci. Rep.* **8**, 10159 (2018).
21. Robinson, A. *et al.* Molecular quantification of Plasmodium parasite density from the blood retained in used RDTs. *Sci. Rep.* **9**, 5107 (2019).
22. Nag, S. *et al.* Proof of concept: used malaria rapid diagnostic tests applied for parallel sequencing for surveillance of molecular markers of anti-malarial resistance in Bissau, Guinea-Bissau during 2014–2017. *Malar. J.* **18**, 252 (2019).

23. Nguyen, T. T. *et al.* DNA recovery from archived RDTs for genetic characterization of *Plasmodium falciparum* in a routine setting in Lambaréné, Gabon. *Malar. J.* **18**, 336 (2019).
24. Ndiaye, M. *et al.* Country-Wide Surveillance of Molecular Markers of Antimalarial Drug Resistance in Senegal by Use of Positive Malaria Rapid Diagnostic Tests. *Am. J. Trop. Med. Hyg.* **97**, 1593–1596 (2017).
25. Cook, J. *et al.* Trends in parasite prevalence following 13 years of malaria interventions on Bioko island, Equatorial Guinea: 2004–2016. vol. 17 (2018).
26. Lu, F. *et al.* Emergence of Indigenous Artemisinin-Resistant *Plasmodium falciparum* in Africa. *N. Engl. J. Med.* **376**, 991–993 (2017).
27. Murphy, S. C. *et al.* Real-time quantitative reverse transcription PCR for monitoring of blood-stage *Plasmodium falciparum* infections in malaria human challenge trials. *Am. J. Trop. Med. Hyg.* **86**, 383–394 (2012).
28. Seilie, A. M. *et al.* Beyond Blood Smears: Qualification of *Plasmodium* 18S rRNA as a Biomarker for Controlled Human Malaria Infections. *Am. J. Trop. Med. Hyg.* **100**, 1466–1476 (2019).
29. Otto, T. D. *et al.* New insights into the blood-stage transcriptome of *Plasmodium falciparum* using RNA-Seq. *Mol. Microbiol.* **76**, 12–24 (2010).
30. Hanron, A. E. *et al.* Multiplex, DNase-free one-step reverse transcription PCR for *Plasmodium* 18S rRNA and spliced gametocyte-specific mRNAs. *Malar. J.* **16**, 208 (2017).
31. Stanistic, D. I., McCarthy, J. S. & Good, M. F. Controlled Human Malaria Infection: Applications, Advances, and Challenges. *Infect. Immun.* **86**, (2018).
32. Krähenbühl, S. *et al.* ELIMU-MDx: a web-based, open-source platform for storage, management and analysis of diagnostic qPCR data. *BioTechniques* (2019).
33. Kamau, E. *et al.* K13-Propeller Polymorphisms in *Plasmodium falciparum* Parasites From Sub-Saharan Africa. *J. Infect. Dis.* **211**, 1352–1355 (2015).
34. Association of mutations in the *Plasmodium falciparum* Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis. *BMC Med.* **17**, (2019).

35. Taylor, S. M. *et al.* Absence of Putative Artemisinin Resistance Mutations Among *Plasmodium falciparum* in Sub-Saharan Africa: A Molecular Epidemiologic Study. *J. Infect. Dis.* **211**, 680–688 (2015).
36. Xu, C. *et al.* Surveillance of Antimalarial Resistance *Pfcr* , *Pfmdr1* , and *Pfkelch13* Polymorphisms in African *Plasmodium falciparum* imported to Shandong Province, China. *Sci. Rep.* **8**, 1–9 (2018).
37. Choi, Y. & Chan, A. P. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. *Bioinformatics* **31**, 2745–2747 (2015).
38. Rubio, J. M. *et al.* Semi-nested, multiplex polymerase chain reaction for detection of human malaria parasites and evidence of *Plasmodium vivax* infection in Equatorial Guinea. *Am. J. Trop. Med. Hyg.* **60**, 183–187 (1999).
39. Guerra-Neira, A. *et al.* *Plasmodium* diversity in non-malaria individuals from the Bioko Island in Equatorial Guinea (West Central-Africa). *Int J Health Geogr* **5**, 27 (2006).
40. Guerra, M. *et al.* *Plasmodium falciparum* Genetic Diversity in Continental Equatorial Guinea before and after Introduction of Artemisinin-Based Combination Therapy. *Antimicrob. Agents Chemother.* **61**, (2016).
41. Eboumbou Moukoko, C. E. *et al.* K-13 propeller gene polymorphisms isolated between 2014 and 2017 from Cameroonian *Plasmodium falciparum* malaria patients. *PLoS ONE* **14**, (2019).
42. Roper, C. *et al.* Molecular surveillance for artemisinin resistance in Africa. *Lancet Infect. Dis.* **14**, 668–670 (2014).
43. Padley, D. J. *et al.* Establishment of the 1st World Health Organization International Standard for *Plasmodium falciparum* DNA for nucleic acid amplification technique (NAT)-based assays. *Malar. J.* **7**, 139 (2008).
44. Brancucci, N. M. B. *et al.* Lysophosphatidylcholine Regulates Sexual Stage Differentiation in the Human Malaria Parasite *Plasmodium falciparum*. *Cell* **171**, 1532-1544.e15 (2017).
45. Hofmann, N. *et al.* Ultra-Sensitive Detection of *Plasmodium falciparum* by Amplification of Multi-Copy Subtelomeric Targets. *PLOS Med.* **12**, e1001788 (2015).

46. Jongo, S. A. *et al.* Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants. *Am. J. Trop. Med. Hyg.* **100**, 1433–1444 (2019).
47. Schindler, T. *et al.* Molecular monitoring of the diversity of human pathogenic malaria species in blood donations on Bioko Island, Equatorial Guinea. *Malar. J.* **18**, 9 (2019).
48. Zainabadi, K. *et al.* A novel method for extracting nucleic acids from dried blood spots for ultrasensitive detection of low-density Plasmodium falciparum and Plasmodium vivax infections. *Malar. J.* **16**, 377 (2017).
49. Kamau, E., Alemayehu, S., Feghali, K. C., Saunders, D. & Ockenhouse, C. F. Multiplex qPCR for Detection and Absolute Quantification of Malaria. *PLoS ONE* **8**, 1–9 (2013).
50. Kamau, E. *et al.* Measurement of parasitological data by quantitative real-time PCR from controlled human malaria infection trials at the Walter Reed Army Institute of Research. *Malar. J.* **13**, 288 (2014).
51. Chua, K. H. *et al.* Development of High Resolution Melting Analysis for the Diagnosis of Human Malaria. *Sci. Rep.* **5**, 15671 (2015).
52. Rougemont, M. *et al.* Detection of four Plasmodium species in blood from humans by 18S rRNA gene subunit-based and species-specific real-time PCR assays. *J. Clin. Microbiol.* **42**, 5636–5643 (2004).
53. Phuong, M., Lau, R., Ralevski, F. & Boggild, A. K. Sequence-based optimization of a quantitative real-time PCR assay for detection of Plasmodium ovale and Plasmodium malariae. *J. Clin. Microbiol.* **52**, 1068–1073 (2014).
54. Cnops, L., Jacobs, J. & Van Esbroeck, M. Validation of a four-primer real-time PCR as a diagnostic tool for single and mixed Plasmodium infections. *Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.* **17**, 1101–1107 (2011).
55. Divis, P. C. S., Shokoples, S. E., Singh, B. & Yanow, S. K. A TaqMan real-time PCR assay for the detection and quantitation of Plasmodium knowlesi. *Malar. J.* **9**, 344 (2010).

487 **Acknowledgments**

488 Etienne Guirou and Charlene Yoboue are recipients of Swiss Government Excellence Scholarships
489 (Number 2016.1250 and 2017.0748, respectively) granted by the State Secretariat for Education,
490 Research and Innovation. We would like to thank Christin Gumpp, Christian Scheurer and Sergio
491 Wittlin from the Swiss TPH Malaria Drug Discovery Group for their help with cultivating PfNF54,
492 PfDD2 and PfHB3 parasites. We are grateful to Eva Hitz and Till Voss from the Swiss TPH Malaria
493 Gene Regulation Unit for kindly providing with *Pf* gametocytes culture.

494

495 **Authors' contributions**

496 Conceptualization: EAG, TS, CD

497 Data curation and validation: EAG, TS, OTD

498 Formal analysis and visualization: EAG, TS

499 Funding acquisition: CD, MT, CM, BMN

500 Investigation: JS, NS, HM

501 Methodology: EAG, SH, GC, AD, LG, MM, CAY

502 Resources: SA, NS, JS, SLH, GM, CCF, WPP, GAG

503 Software: SK

504 Project administration and supervision: CD, TS

505 Writing – original draft: EAG, TS, CD

506 **Competing interests**

507 SL Hoffman is salaried and full-time employee of Sanaria Inc, the developer and sponsor of Sa-
508 naria® PfSPZ Vaccine. He was not responsible for the collection, recording or entry of the parasito-
509 logical data used in this study. The other authors have no conflicts of interest.

510 **Funding**

511 This study was funded by a public–private partnership, the Equatorial Guinea Malaria Vaccine Ini-
512 tiative (EGMVI), made up of the Government of Equatorial Guinea, Marathon EG Production Lim-
513 ited, Noble Energy, and Atlantic Methanol Production Company.

514

515 **Ethics approval and consent to participate**

516 For the school-based survey in Mkuranga district, sample collection was approved by the Senate
517 Research and Publication Committee (SRPC) of the Muhimbili University of Health and Allied Sci-
518 ences and the respective authorities at Mkuranga district.

519 Both clinical trials were performed in accordance with Good Clinical Practices (GCP). CHMI-1
520 (Clinical Trials.gov: NCT02613520) protocol was approved by IRBs of the Ifakara Health Institute
521 (IHI) (Ref. No. IHI/IRB/ No: 32-2015), the National Institute for Medical Research Tanzania
522 (NIMR) (NIMR/HQ/R.8a/Vol.IX/2049), and the Ethikkommission Nordwest- und Zentralschweiz
523 (EKNZ) Switzerland (reference number 15/104). The protocol was also approved by the Tanzania
524 Food and Drug Authority (TFDA) (Auth. No. TZ15CT013). CHMI-2 (Clinical Trials.gov:
525 NCT03420053) protocol was approved by IHI’s IRB (Ref. No. IHI/IRB/ No: 32-2015), NIMR
526 (NIMR/HQ/R.8a/Vol.IX/2049), EKNZ (reference number 15/104) and TFDA (Auth. No.
527 TZ15CT013). The 2018 malaria indicator survey was approved by the Ministry of Health and So-
528 cial Welfare of Equatorial Guinea and the Ethics Committee of the London School of Hygiene &
529 Tropical Medicine. Written informed consent was obtained from all adults and from parents or
530 guardians of children who agreed to participate. Only samples for which an additional consent for
531 molecular analysis was obtained were included in this study.

532 We confirm that all experiments were performed in accordance with relevant guidelines and regula-
533 tions.

534

535 **Abbreviations**

536 *Pf* (*P. falciparum*), pfk13 (*Pf* kelch 13), RDT (rapid diagnostic test), DBS (dried blood spot), ENAR
537 (extraction of nucleic acids from RDT), CHMI (controlled human malaria infection), NA (nucleic
538 acid), NAT (nucleic acid amplification technique), PfIS (WHO International standard for *P. fal-*
539 *ciparum* NAT), LOD (limit of detection), RT (room temperature), qPCR (quantitative polymerase
540 chain reaction), PlasQ (multiplex qPCR assay for quantification of *P. falciparum* and *Plasmodium*
541 *spp.* parasites), SNP (single nucleotide polymorphism), Pf/ μ L (*Pf* parasites per μ L blood)

542

543 **Figure legends**

544

545 **Figure 1. Extraction and detection of *Pf* NAs from used RDTs.** A) Recovery rates of *Pf* DNA
546 from RDTs collected in asymptomatic Tanzanian school children. B) Comparison of extraction per-
547 formance of four protocols based on Cq values of the human *masep* gene. C) Association of para-
548 site densities and Cq values of freshly prepared *Pf* strains (PfDD2, PfHB3 and PfNF54). Gray col-
549 our indicates failed detection. D) Correlation between parasite densities of serially diluted PfIS and
550 Cq values for PlasQ targets. Red coloured dots represent samples where amplification failed.

551

552 **Figure 2. Evaluation of ENAR protocol using samples collected during CHMI studies.** A) *Pf*
553 detection rates grouped by parasite density and storage time. B) Quantification ratio between densit-
554 ies derived from ENAR and densities derived from whole blood qPCR (WB-qPCR). C) Diagnostic
555 sensitivity of rapid diagnostic test (RDT), ENAR followed by qPCR detection (qPCR) and ENAR
556 followed by RT-qPCR detection (RT-qPCR) in relation to parasite density. Rolling means of 10 ob-
557 servations, using WB-qPCR as a gold standard, are shown with 95% CIs (shaded areas). D) Correl-
558 ation of parasite densities obtained from DNA extracted from fresh whole blood and NAs extracted
559 by ENAR.

560 **Figure 3. Adaptation of ENAR protocol for analyzing large numbers of barcoded RDTs.** A)
561 Malaria indicator survey conducted including a detailed questionnaire. B) Malaria prevalence is de-
562 termined by RDT followed by storage of barcode-labelled RDTs. C) Sorting and tracking of RDTs
563 using smartphone apps. D-F) High throughput protocol for extraction of NAs from RDTs using the
564 ENAR approach. G) Detection and quantification of *Pf* and non-*Pf* malaria parasite. H) Automated
565 analysis of qPCR data using ELIMU-MDx. I) Genotyping of *pfk13* propeller region for drug resist-
566 ance monitoring.

567

568 **Figure 4. Parasite densities among asymptomatic individuals and implication for sequence**
569 **analysis.** A) Age group dependent parasite densities. B) Association between parasite density and
570 successful amplification of *pfk13* for sequence analysis.

571 **Supplementary Information**

572

573 **Supplementary Table S1.** Summary of published studies using DNA extracted from RDTs for mo-
574 lecular analysis of malaria parasites.

575

576 **Supplementary Protocol S1.** Extraction of Nucleic Acids from RDTs (ENAR): step-by-step pro-
577 tocol

578

579 **Supplementary Figure S1.** Accumulation of captured *Pf* NAs on RDTs.

580

581 **Supplementary Figure S2.** Detection of the gametocyte-specific transcript PF3D7_0630000 in
582 blood on RDTs after three weeks of storage at RT.

Table 1. Overview of blood samples collected during two CHMIs and stored on RDTs.

Study (Year)	CHMI-1 (2016) > 18 months storage	CHMI-2 (2018) < 1 month storage
RDT brand	BinaxNOW® Malaria RDT	CareStart™ Malaria (Pf/PAN) Combo
Number of RDTs collected	71	50
Blood volume on RDT	20 µL	5 µL
Storage time in days (mean and range)	605 (596-616)	18 (10-48)
Storage conditions	RT	RT
Sampling days post CHMI (mean and range)	14.0 (10.5-18.0)	12.7 (9.0-18.0)
% positive by WB-qPCR	38.0% (27/71)	62.0% (31/50)
WB-qPCR parasite density (parasites/µL, geom. mean and range)	4.7 (0.05-840.0)	0.3 (0.01-1041.0)

Table 2. Demographic information of MIS participants.





	All individuals (n=13270)	Selected individuals (n=2690)
Gender		
female	7155 (53.9 %)	1569 (58.3 %)
male	6115 (46.1 %)	1121 (41.7 %)
Age (years)		
Mean (SD)	21.2 (\pm 17.7)	27.1 (\pm 21.0)
Age group		
<5	2308 (17.4 %)	276 (10.3 %)
5-14	3719 (28.0 %)	660 (24.5 %)
15-45	5758 (43.4 %)	1208 (44.9 %)
>45	1485 (11.2 %)	546 (20.3 %)
District		
Baney	1519 (11.4 %)	400 (14.9 %)
Luba	1093 (8.2 %)	268 (10.0 %)
Malabo	10121 (76.3 %)	1814 (67.4 %)
Riaba	537 (4.0 %)	208 (7.7 %)
RDT result		
negative	11842 (89.2 %)	1623 (60.3 %)
pLDH	43 (0.3 %)	39 (1.4 %)
PfHRP2	871 (6.6 %)	653 (24.3 %)
pLDH+PfHRP2	462 (3.5 %)	367 (13.6 %)
Pregnancy status		
currently pregnant	237 (1.8 %)	225 (8.4 %)
gave birth to live baby	918 (6.9 %)	128 (4.8 %)
Hemoglobin (g/dL)		
Mean (SD)	12.4 (\pm 1.79)	12.1 (\pm 1.88)
Anemia status		
no	8874 (65.7 %)	1593 (57.6 %)
mild	2711 (20.1 %)	634 (22.9 %)
moderate	1777 (13.2 %)	502 (18.1 %)
severe	110 (0.8 %)	34 (1.2 %)





Table 3. ENAR-based identification of malaria parasites using PlasQ RT-qPCR assay.

	number of samples (%)
RDTs analysed by PlasQ	2690
Positive for PlasQ RT-qPCR	828 (30.8%)
<i>Plasmodium</i> spp. identification	
Positive for <i>P. falciparum</i>	769 (92.9%)
<i>P. falciparum</i> with >100 Pf/ μ L	227 (29.5%)
Positive for <i>P. malariae</i>	33 (4.0%)
Positive for <i>P. ovale</i> spp.	8 (1.0%)
Positive for <i>P. knowlesi</i>	0 (0.0%)
Positive for <i>P. vivax</i>	0 (0.0%)
<i>Pf/Pm</i> co-infections	16 (1.9%)

Table 4. *Pfk13* propeller polymorphisms observed in MIS population on Bioko Island.

Kelch13 propeller genotyping	PROVEAN score	
<i>P. falciparum</i> strains sequenced	290	
PfNF54 allele	283 (97.6%)	
Non-synonymous SNPs		
A578S (G1732T)	2 (0.69%)	-1.962
V589I (G1765A)	1 (0.35%)	-0.663
V517I (G1549A)	1 (0.35%)	-0.562
P553L (C1659T)	1 (0.35%)	-1.721
Synonymous SNPs		
V510V (G1530A)	1 (0.35%)	
C469C (C1407T)	1 (0.35%)	







A. Malaria indicator survey with high population coverage




B. Malaria diagnosis using RDT followed by storage of barcode-labelled RDTs




C. Identification and tracking of distinct RDTs with mobile phone apps *RDTselect* and *RDTallocator*




D. RDT strip is removed from shell with single use forceps to avoid cross-contamination.



E. Horizontal incubation of entire uncut RDT strip for total recovery of NA



F. High-throughput purification of NA using 96-well format *ENAR* protocol



G. Systematic identification and quantification of *Plasmodium spp.* parasites using PlasQ assay



H. Automated qPCR data management, quality control and analysis using *ELIMU-MDx* platform



I. Sequencing of *pfk13* propeller region for drug resistance monitoring of local *P. falciparum* strains

